Q2 FY2026 EarningsQ2 FY26 beat consensus across key top and bottom-line metrics, with revenue of $16.99B exceeding the $16.76B mean estimate (+1.4%). Normalized EPS reached $3.61, slightly ahead of the $3.608 mean. Growth was driven by a 24.4% surge in Skyrizi sales ($5.51B) and 24.5% growth in Rinvoq ($2.53B), more than offsetting the 35.9% decline in Humira due to biosimilar erosion. Management confirmed the proposed $10.9B acquisition of Apogee Therapeutics, signaling a strategic focus on expanding the immunology pipeline.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Abbvie(ABBV) the Revenue is 16.99 B (+10.16%), Beat estimate;the EBIT is 8.213 B (+20.2%), Beat estimate;the EPS is 2.03 (+290.4%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
16.99B10.16%
16.76B8.68%
+0.23B1.48%
EBITExceed expectations
8.21B20.20%
8.10B18.59%
+0.11B1.61%
EPSExceed expectations
2.03290.38%
1.9107267.44%
+0.119322.94%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf